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Significant morphological change in osteoarthritic hips identified 1 
over 6-12 months using Statistical Shape Modelling.  2 
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 Abstract 30 
Objective Predicting who will develop osteoarthritis, assessing how rapidly their disease will 31 
progress and monitoring early responses to treatment are key to the development of 32 
therapeutic agents able to treat this crippling disease and to their future clinical use. 33 
Statistical Shape Modelling (SSM) enables quantification of variations in multiple geometric 34 
measures describing the whole hip joint to be considered in concert. This prospective study 35 
evaluates the responsiveness of SSM to changes in hip-shape within one year. 36 
Methods Sixty-two people, mean age 67.1 yrs, were recruited. Dual-energy X-ray 37 
Absorptiometry images were taken at three timepoints (baseline, six and twelve months). 38 
Based on Kellgren-Lawrence grading (KLG)) of their baseline images, subjects were classified 39 
into control/doubtful OA: KLG<1 in both hips; moderate OA: KLG=2; and severe OA: KLG≥3 40 
in their most severe hip. Morphology was quantified using SSM and changes in shape were 41 
assessed using generalised estimating equations. Standardized response means (SRM) were 42 
calculated for the first and second 6 month periods, then the full 12 months. 43 
Results Disease severity ranged from KLG0-KLG4 in the 124 hips assessed at baseline. Three 44 
SSM modes (Modes 1, 3 and 4) were associated with OA severity. Across the whole cohort, 45 
SRM magnitudes ranged from 0.16 to 0.63. The greatest subgroup SRM (magnitude 0.91) 46 
was observed over 12 months in those subjects with moderate OA (KLG2). 47 
Conclusions We have demonstrated that SSM can capture changes in hip shape over 6 and 48 
12 months across the entire hip joint providing a sensitive measure of hip OA progression. 49 
 50 
Keywords: osteoarthritis; statistical shape modelling; morphology; hip; radiographic; DXA 51 
 52 
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Introduction 1 
Despite the high prevalence of osteoarthritis (OA) there is a dearth of treatments that can 2 
modify disease progression, leaving patients with symptomatic relief alone until a joint 3 
replacement becomes their only option. Among the reasons for the lack of Disease 4 
Modifying Osteoarthritis Drugs (DMOADs) are our current inabilities to predict who will 5 
develop OA, assess how rapidly their disease will progress and monitor treatment success. 6 
 7 
The diagnosis of radiographic OA is made using semi-quantitative scoring systems such as 8 
Kellgren-Lawrence grades (KLG), Croft or ACR [1-3]. These scoring systems assign a score to 9 
each joint based on a number of primary radiographic features of joint disease including: 10 
deformation of the femoral head, osteophytes, subchondral cysts, subchondral sclerosis and 11 
reduced joint space width.  Although these scoring systems are adequate for radiographic 12 
disease diagnosis and broad stratification into control/doubtful, moderate and severe OA 13 
they are not sensitive enough to provide a useful tool for the identification of subjects likely 14 
to progress rapidly nor for treatment monitoring in clinical trials.  15 
 16 
Joint space width (JSW), a surrogate marker of cartilage loss, is a quantitative measure of OA 17 
progression and is currently the only Federal Drugs Administration-approved measure of OA 18 
progression. JSW is used as an endpoint in clinical trials of all new DMOADs. However, joint 19 
space narrowing focuses on a single feature in a single tissue in a multi-tissue, multi-feature 20 
disease.  21 
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 22 
In recent years, magnetic resonance imaging has become the mainstay of much of the 23 
ongoing OA research on disease progression. There is no doubt that data gained from MR 24 
images are invaluable in providing detailed information on bone marrow lesions, cysts and 25 
cartilage erosion. However, MR imaging is not suitable for all hip OA patients; not only is it 26 
costly but many patients are simply too obese to fit in a standard MR scanner.  27 
 28 
Dual energy X-ray Absorptiometry (DXA) is an imaging modality used in the diagnosis of 29 
osteoporosis. In addition to bone mineral density (BMD) data, modern high-resolution 30 
scanners, such as the GELunar iDXA, generate near radiographic quality images. These 31 
images are currently under-utilised, simply being used to check positioning when capturing 32 
BMD data. We have previously demonstrated that these images can be used to grade 33 
radiographic OA severity as repeatably as from radiographs [4]. 34 
 35 
Statistical shape modelling (SSM) uses Principal Component Analysis to describe variation in 36 
the complicated shapes of natural objects [5]. SSMs have previously been applied to images 37 
captured by different imaging modalities taken from a number of different sites within the 38 
human body including heart [5], brain [6], spine [7, 8], hip [9, 10] and leg [11]. In the context 39 
of this study the SSM is applied to hip images captured from an iDXA. This allows variations 40 
in multiple geometric measures to be considered in concert thus describing the hip joint as a 41 
whole. Each principal component, or mode of variation, describes a different aspect of hip 42 
shape. By applying the SSM to a series of hip images from the same individual taken at 43 
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intervals allows the investigation of how the shape of the hip changes as a function of time. 44 
In recent years, studies using SSM have shown that the resultant models can act as a 45 
biomarker for musculoskeletal disorders of the hip, predicting hip fractures in osteoporotic 46 
cohorts [10, 12-14] and incidence and progression of osteoarthritis, including total hip 47 
replacement [9, 15-21]. 48 
 49 
Standardized Response Mean (SRM) (the mean difference between two measurements 50 
divided by the standard deviation of the difference) is an effect size index that is frequently 51 
used in medicine to gauge clinical change over time. Biomarkers with higher responsiveness 52 
are desirable for clinical trials as this indicates trials could be shorter and more cost-53 
effective. 54 
 55 
In this study we examine the change in hip shape mode scores over a 12 month period using 56 
DXA images captured from a mixed-sex cohort with a range of OA severities at baseline. 57 
 58 
Materials and methods 59 
Subject recruitment 60 
This is a prospective study using subjects recruited from the NHS Grampian Radiology 61 
Information System (RIS). Computerised searches of the database identified subjects aged 62 
>30 years who had undergone an anteroposterior pelvic radiograph or bilateral radiographs 63 
of the hips in the previous 12 months. Radiographic reports were examined by a clinician to 64 
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assess suitability for the study. Subjects were excluded based on the following criteria: 65 
surgical interventions (including total joint replacement and osteotomies), clear radiological 66 
evidence of inflammatory arthritis, congenital / developmental dysplasia, avascular necrosis, 67 
metabolic bone disease, or absence of a formal report on the RIS.  68 
 69 
Following subject identification, letters were sent to the physician who initially referred the 70 
subject for the radiograph to seek their help in recruiting the subject into the study (no 71 
incentive was offered). The referring physician was asked to send an information pack to the 72 
subject. Subjects were asked to complete a contact form and return it, to indicate interest in 73 
participating in the study. 74 
 75 
Written informed consent was obtained when subjects attended for bone density 76 
assessment, in accordance with the declaration of Helsinki. The Grampian Research Ethics 77 
Committees approved the study (ref. 06/S0801/116) 78 
 79 
Radiographic grading 80 
The radiographs of subjects who agreed to participate in the study were scored for OA 81 
severity in both hips, by a single reader blinded to the clinical diagnosis, using the Kellgren-82 
Lawrence system (KLG) [1, 22]. Subjects were classified into control/doubtful OA according 83 
to the most severe hip or the right hip if both hips scored the same KLG: KLG no more than 1 84 
in either hip; moderate OA: KLG no more than 2; and severe OA: KLG of at least 3 in one hip 85 
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based on the KLG of their most severe joint. Subjects recruited into the study underwent 86 
Dual Energy X-ray absorptiometry (DXA) scans (iDXA GE Lunar) of both hips on entry and 87 
after 6 and 12 months. 88 
 89 
Statistical Shape Modelling 90 
The detail of the statistical shape modelling technique (SSM) used has been described 91 
elsewhere [23]. In brief, Statistical Shape Modelling uses a set of “landmark points” to 92 
describe the outline of an object. Each landmark point refers to the same location in every 93 
image (for example the base of the lesser trochanter), allowing the variation in shape to be 94 
measured across different images, and all the images from both hips at all three visits (0, 6 95 
and 12-month time-points) were included in the model.  96 
 97 
The landmark points were placed using the active shape modelling toolkit (Visual 98 
Automation Limited, Manchester, UK), a software program that runs within MATLAB (The 99 
Math Works Inc, Natick, United states) software environment, and analysed using custom 100 
made software (SHAPE, Aberdeen University, Aberdeen, UK). The analysis performs a 101 
Procrustes transformation, to remove effects of overall size, before applying principal 102 
components analysis to generate a series of orthogonal modes that describe the variations 103 
in shape within the set of images. The modes are scaled to have a mean of zero and unit 104 
standard deviation for the whole image set. Each image is then given a score to describe 105 
how far the shape lies from the mean shape for each mode. 106 
 107 
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In this study we built a 55-point SSM. This model included the proximal femur, part of the 108 
acetabulum and osteophytes, allowing visualization of common radiographic features 109 
observed in OA (Figure 1).  110 
 111 
Figure 1 here 112 
 113 
Statistical Analysis 114 
Comparison between the groups at baseline was performed using one-way ANOVAs for 115 
continuous variables (or Kruskal-Wallis ANOVA on Ranks if data were not normally 116 
distributed determined using the Shapiro-Wilk test) and a Chi-squared test for sex balance. 117 
To account for multiple measures from the same person (both hips, multiple visits) 118 
Generalized Estimating Equations (GEE) were used to investigate the relationship between 119 
shape, KLG and changes between visits after adjustment for age, sex and BMI (SPSS v22, 120 
IBM corp). Both hips were included at each time-point and the dependent variable was the 121 
mode of interest. Missing data were excluded. A separate GEE was run for each mode. 122 
Variables analysed were Baseline KLG, Visit (in months), age at baseline, sex, BMI and the 123 
interaction between visit and baseline KLG. An autoregressive correlation matrix (AR(1)) was 124 
used. The distribution was set to ‘normal’ and link to ‘identity’.  This generates a measure of 125 
the slope of the relationship, B, and its 95% confidence interval (CI) as well as a P-value, 126 
which we used merely as a guide. We took results to be statistically significant when the 127 
95% CI did not contain zero. Where statistically significant (P<0.05) changes over time (with 128 
visit) were observed, Standardised Response Means (SRM) and 95% confidence intervals 129 
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were calculated using the hip with the highest KLG for each person (Medcalc version15, 130 
Ostend, Belgium). The SRM scales the difference between the means of two sequential 131 
measurements by the standard deviation of the differences and enables measures of 132 
different magnitudes to be compared. This allowed direct comparison of the responsiveness 133 
with other published imaging measures used in OA. 134 
 135 
Results 136 
In total, 62 subjects (37 female and 25 male) were recruited into this study. At baseline, 14 137 
hips were graded as KLG 0, 49 as KLG 1, 34 as KLG 2, 16 as KLG 3 and 11 as KLG 4. KLG was 138 
determined from the baseline radiograph taken in the preceding 12 months. The average 139 
time between radiograph and baseline iDXA scan was 225 ± 104 days. The mean time 140 
between baseline and the 6-month DXA scans was 174 (17) days, between 6- and 12-month 141 
DXA scans was 182 (18) days and for baseline DXA to 12-month DXA scan was 357 (30) days. 142 
All three scans were obtained from 50 of the participants; eight had no 6-month DXA scan 143 
and a further four did not receive a 12-month DXA scan. Table 1 shows the results of tests 144 
for differences in the distribution of age, sex or BMI between the three severity groups 145 
(control/doubtful, moderate and severe OA) at baseline. BMI was not normally distributed 146 
(Shapiro-Wilk P=0.034), so Kruskal-Wallis ANOVA on Ranks was applied. No statistically 147 
significant differences were observed for age (P=0.37), BMI (P=0.084) or sex (P=0.067).  148 
Table 1 near here 149 
 150 
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A scree plot [24], showing the amount of variance in the model described by each mode, 151 
was used to select the first 5 modes of variation. Mode 1 described 22.2% and mode 5 4.4% 152 
of the variance. Together these 5 modes explained over 55% of the total variance and each 153 
subsequent mode described less than 4% of the variance in the model.  154 
 155 
These first 5 modes were analysed for association with KLG using GEE. After adjustment for 156 
age, sex and BMI, statistically significant associations with KLG were observed in three 157 
modes; mode 1 (P < 0.0001, Β = –0.29 (95% CI = –0.381, –0.19)), mode 3 (P = 0.001, Β = 0.29 158 
(95% CI = 0.12, 0.46)) and mode 4 (P = 0.014, Β = 0.18 (95% CI = 0.04, 0.32)). Of these, two 159 
also showed significant differences with visit, mode 1 (P < 0.0001, Β = –0.036 (95% CI = –160 
0.051, –0.021)) and mode 4 (P < 0.0001, Β = –0.037 (95% CI = –0.054, –0.019)).  161 
 162 
Examining these three modes further, by including interaction terms between KLG and visit, 163 
showed significant interactions for modes 3 (P = 0.009, Β = –0.018 (95% CI = –0.032, –164 
0.005)) and 4 (P < 0.009, Β = –0.022 (95% CI = –0.038, –0.005)), but no interaction for mode 165 
1 (P = 0.26). All three modes associated with KLG were significantly associated with sex and 166 
modes 1 and 4 were also linked to BMI (P ≤ 0.05). Two modes (Modes 2 and 5) were 167 
associated with age (P < 0.05) but were not linked to any other input variables in the model. 168 
 169 
Figure 2 shows the variations in shape described by modes 1, 3 and 4. Decreasing Mode 1 170 
values (from +2sd to –2sd) show all the classical features of radiographic osteoarthritis: 171 
increasing size of superior and inferior femoral head osteophytes, joint space narrowing and 172 
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deformation of the femoral head. In addition, there is also a reduction in neck shaft angle, 173 
some uncovering of the femoral head and an increase in neck width. Increasing Mode 3 174 
values (from –2sd to +2sd) were associated with superior and inferior femoral head 175 
osteophytes and with uncovering of the femoral head. Increasing mode 4 values (from –2sd 176 
to +2sd) were associated with growth of a superior femoral head osteophyte but not 177 
inferior osteophytes and a decrease in neck shaft angle. 178 
 179 
Figure 2 near here 180 
 181 
The average mode 1 score decreased over the course of the 12-month follow-up and was 182 
also found to have a negative association with KLG. Whilst the average mode 4 score also 183 
decreased with visit this showed an inverse relationship with OA severity. Investigating the 184 
effect size of these changes SRM values were calculated from the hip with the highest KLG 185 
at baseline (used for severity grouping) over the first and second 6-month periods, then for 186 
the full 12 months for modes 1,3 and 4 (Table 2). Further analysis by severity group (Table 3) 187 
revealed the largest change in mode 1 was seen in those with moderate OA (12-month 188 
SRM=-0.91 [-1.36, -0.55]) followed by those with severe OA (12-month SRM=-0.61 [-1.26, -189 
0.07]). In the control/doubtful OA group, mode 3 showed the largest changes (12-month 190 
SRM=0.66 [0.26, 1.06]).  Whilst in the severe group mode 4 was the most sensitive (12-191 
month SRM=-0.67 [-1.33, -0.10]).  192 
Table 2 near here 193 
Table 3 near here 194 
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 195 
Discussion  196 
Data from this study demonstrate that SSM is a sensitive imaging biomarker that can 197 
capture morphological changes in the hip over a period as short as 6 months, but more 198 
reliably over 12 months. We observed a significant association between hip shape and OA 199 
disease severity in three modes (Modes 1, 3 and 4) in this model. There was a rise in SRM 200 
between 0-6 and 0-12 months when the cohort was analysed as a whole for each of the 201 
modes. The SRM values reported here (-0.63, 0.44 and -0.40 for modes 1, 3 and 4 202 
respectively over 12 months) are greater than those reported elsewhere in the literature for 203 
a single measure over this timescale (reviewed in [25]), demonstrating improved 204 
responsiveness to disease progression. Further, analysis by severity grouping revealed the 205 
greatest change was observed over 12 months in the moderate OA group (Mode 1 SRM -206 
0.91). In addition, even in those patients categorised as having severe OA using the KLG 207 
scoring system (KLG3 or 4) at baseline we were still able to demonstrate a progression over 208 
12 months by shape changes captured by mode 1 (SRM -0.61) and mode 4 (SRM -0.67). 209 
Interestingly, mode 3 appeared to detect changes over 12 months in individuals starting 210 
with no or doubtful OA with a comparable SRM of 0.66. The variability between the SRMs 211 
for the first and the second 6-month periods indicates that although changes may be 212 
detected in six months this is not as reliable as over the full 12 months when the changes 213 
are more consistent.  Whilst there are, as yet, no DMOADs, new drugs that are in the early 214 
stage of development are likely to work most effectively in mild to moderate OA subjects. 215 
When therapies become available to slow radiological progression in OA SSM would then 216 
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provide a sensitive means of measuring these changes, especially in early and moderate 217 
disease but also even in those with the most advanced OA.  218 
 219 
Unsurprisingly, the shape model showed strong links with KLG, especially Mode 1 in which a 220 
lower score was associated with the growth of osteophytes, femoral head and neck 221 
deformation and joint space narrowing (Figure 2). One strength of the SSM approach is that 222 
all of these features are detected simultaneously and a score assigned on a continuous 223 
scale; they do not have to be assessed separately and graded on an ordinal scale. The 224 
patterns observed by shape modes presented here match well with geometrical features 225 
observed by other studies. For example, a decreased neck shaft angle, as seen in Mode 3 226 
and Mode 4 was identified as a risk factor for OA by Doherty et al 2008 [26]. Deformation of 227 
the femoral head, such as the non-spherical shape observed with low mode 1 scores has 228 
also been identified previously in OA [26] as has the further deformation that occurs with 229 
the progression of OA, with the femoral head becoming increasingly mushroom-shaped [15, 230 
19, 20]. This sometimes-dramatic change in shape is included in the semi-quantitative 231 
Kellgren-Lawrence grading system for moderate and severe cases. The uncovering of the 232 
femoral head, as seen in mode 1 and 3 is a feature also captured in the Chingford cohort 233 
using the Hip Morph software [27]. Statistical Shape Modelling allows quantification of 234 
these effects and identifies feature that co-occur. This enables changes over periods as 235 
short as 6 to12 months to be measured (as shown here) or, as found previously, over a 236 
period up to 5 years [19]. 237 
 238 
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Joint space width (JSW) is the current gold standard for clinical trials assessing structural 239 
progression of OA. Whilst much of the focus has been on the knee a number of studies have 240 
investigated hip OA progression and these provide a useful effect size comparator. Few are 241 
as good over a period as short as 6-12 months as those presented in this study. A systematic 242 
review published in 2011 pooled 11 studies measuring minimum JSW in a meta-analysis 243 
[25]. The overall SRM for the pooled data was 0.66. This is similar to the SRM for our mode 1 244 
data, although the average time to follow-up was not reported for the pooled data and the 245 
studies included ranged from 1-8 years, whereas our SRM for mode 1 was achieved after 246 
just 1 year of follow-up. Data from individual studies produce SRMs that range from 1.75 to 247 
0.27 [28-32]. Findings from a 1-year study in which subjects started with KLG 2 or 3, 248 
reported a reduction in minimum JSW of 0.52 (0.49) mm (SRM 1.05) [33], which is 249 
comparable with 0.91 observed in the current study when analysing those patients with a 250 
KLG 2 at baseline. Traditionally, the terms 'small,' 'medium,' and 'large' were used by Cohen 251 
to provide a qualitative assessment of the effect size. He pointed out, however, that these 252 
should be treated as relative not only to each other but also to the research method being 253 
employed in any given investigation [34]. Accordingly, we have used SRMs in order to be 254 
able to compare our results with those from studies of JSW, which is measured on a 255 
different scale.  256 
 257 
We are not the only group to use DXA scans to predict OA progression, although others 258 
have used DXA images to measure specific elements of hip geometry and morphometry [17, 259 
35]. The use of DXA images has a number of key advantages over radiographs. The radiation 260 
dose of a bilateral hip iDXA is ~20 µSv, compared with ~700 µSv for a bilateral hip 261 
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radiograph. In addition, patient positioning is also routinely more reproducible than in most 262 
hip or pelvic radiography as position is important for accurate measurement of hip bone 263 
mineral density, the most common use of DXA scanners. This minimizes possible effects due 264 
to internal or external rotation. While the current modality of choice for OA imaging is MRI, 265 
as it provides a 3D image, MRI scans are more expensive and require longer appointments 266 
compared with DXA. In addition, modern DXA scanners, such as the iDXA, can take patients 267 
weighing up to 450 lb, which is a distinct advantage in a disease where obesity is common; 268 
the narrow aperture of an MRI scanner can make it difficult to scan patients whose BMI 269 
exceeds ~35 kg/m
2
. 270 
 271 
OA is gradually undergoing a paradigm shift away from being a disease of articular cartilage 272 
to one of the whole joint or even the whole body. In this respect the use of SSM enables 273 
changes across the whole joint, including contact alignment or coverage, anatomy, cartilage 274 
thickness and osteophytes to be captured. This may contribute to its greater sensitivity to 275 
subtle morphometric changes that appear to provide better biomarkers for incidence and 276 
progression.  Capturing these changes across the entire joint also paves the way to explore 277 
further genetic factors affecting joint shape [36-38].  278 
 279 
As with any study ours has limitations. We classified our patients into 3 groups based on 280 
radiographic OA, which is not necessarily coincident with symptomatic clinical OA.  Patients 281 
recruited for this study were those who had undergone a pelvic or bilateral hip radiograph 282 
in the previous 12 months and it is possible, therefore, that those in the control/doubtful 283 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
group, whilst not exhibiting radiographic OA, may have had clinically symptomatic OA. KLG 284 
was determined from the baseline radiograph and these routine healthcare radiographs 285 
were taken at some time in the preceding 12 months, as described above, which may have 286 
affected group assignment. However, we have previously published data comparing KLG on 287 
recruitment radiographs and baseline DXA images in this cohort that demonstrates that this 288 
time gap had little effect on KLG repeatability [4], highlighting the lack of sensitivity of KLG 289 
as a method for monitoring OA disease progression. It might also have been useful to have 290 
taken matching radiographs at the 6-month time point as this would have allowed us to do a 291 
head to head comparison of change over time DXA vs radiographs using SSM, this was not 292 
done, however, in an effort to minimise radiation exposure in this cohort. Sex and BMI both 293 
approached conventional standards for statistical significance (0.10>P>0.05) and it is 294 
possible that a larger cohort might have led to dividing by sex or having to include BMI as a 295 
covariate. In a recent study of a birth cohort of 1633 individuals imaged using DXA between 296 
the ages of 60-64 years we found that all except one of the first ten modes generated in that 297 
study differed between men and women [39] and that higher BMI throughout adulthood 298 
and greater gains in BMI were associated with a shorter femoral neck and a wider and 299 
flatter femoral head [40]. There was also an interaction between sex and BMI in the current 300 
study with men having a greater BMI than women. This is something that can be explored in 301 
future, larger, studies having shown in the current study that, at least in principle, it is 302 
possible to detect changes over 12 months irrespective of sex or BMI.  303 
 304 
In conclusion, we have demonstrated that SSM can capture changes in hip shape across the 305 
entire joint over a period as short as 6 months, but more reliably, 12 months. This provides a 306 
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sensitive measure of hip OA progression. While similar results may be expected from 307 
carefully positioned radiographic imaging, the use of DXA images demonstrates the utility of 308 
this low-dose imaging modality for the assessment of OA. 309 
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Table 1. Distribution of age, sex and BMI for each severity group comprising N individuals. 476 
Significance differences between groups were tested using Chi-Squared (sex), Kruskal-Wallis 477 
(BMI) and one-way ANOVA (age). 478 
Severity Group N Sex  
N female (%) 
BMI 
Median (25% - 75%) 
Age 
Mean (sd) 
Control/doubtful 20 15 (75%) 32.7 (29.2, 35.5) 64.9 (8.0) 
Moderate 20 13 (65%) 29.1 (25.9, 32.7) 67.5 (7.2)  
Severe 22 9 (40.9%) 28.5 (25.9, 33.9) 68.7 (10.5)  
Total 62 37 (59.7%)  29.7 (27.3, 33.9) 67.1 (8.8) 
P-value  0.067 0.084 0.37 
 479 
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Table 2. Standardized Response Means (SRMs) and 95% confidence intervals for modes 1, 3 481 
and 4 for time periods 0-6 months, 6-12 months and 0-12 months.  482 
 483 
 0-6 months 6-12 months 0-12 months 
Mode 1 -0.41 [-0.68, -0.05] -0.23 [-0.50, 0.05] -0.63 [-0.88], -0.34] 
Mode 3 0.23 [-0.04, 0.47] 0.35 [0.05, 0.64] 0.44 [0.19, 0.68] 
Mode 4 -0.18 [-0.47, 0.08] -0.44 [-0.73, -0.15]] -0.40 [-0.71, -0.11] 
 484 
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Table 3. Standardized Response Means (SRMs) and 95% confidence intervals for modes 1, 3 486 
and 4 for time periods 0-6 months, 6-12 months and 0-12 months when data are split by 487 
severity (control/doubtful, moderate and severe OA). The number of individuals remaining 488 
in each group at each time point are given by N for the first mode. 489 
 490 
  Control/doubtful Moderate Severe 
 0-6 months 
(N) 
-0.11 [-0.61, 0.42] 
19 
-0.64 [-1.28, 0.06] 
19 
-0.43 [-1.00, 0.04] 
16 
Mode 1 6-12 months 
(N) 
-0.38 [-0.99, 0.13] 
19 
0.08 [-0.47, 0.59] 
16 
-0.33 [-0.84, 0.20] 
15 
 0-12 months 
(N) 
-0.40 [-0.84, 0.07] 
19 
-0.91 [-1.36, -0.55] 
16 
-0.61 [-1.26, -0.07] 
15 
 0-6 months 0.07 [-0.41, 0.52] 0.35 [-0.10, 0.78] 0.23 [-0.34, 0.71] 
Mode 3 6-12 months 0.68 [0.16, 1.19] 0.04 [-0.56, 0.48] 0.40 [-0.17, 0.99] 
 0-12 months 0.66 [0.26, 1.06] 0.33 [-0.26, 0.74] 0.39 [-0.25, 0.76] 
 0-6 months 0.12 [-0.38, 0.60] -0.27 [-0.77, 0.20] -0.43 [-0.92, 0.17] 
Mode 4 6-12 months -0.52 [-0.93, -0.03] -0.33 [-0.79, 0.14] -0.44 [--1.15, 0.16] 
 0-12 months -0.18 [-0.65, 0.34] -0.39 [-0.99, 0.09] -0.67 [-1.33, -0.10] 
 491 
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Figure captions 493 
Figure 1. Design for the hip SSM, comprising the proximal femur, part of the acetabulum 494 
and osteophytes. In the absence of the feature identified in colour, (e.g an osteophyte) the 495 
points collapse back on to the primary outline. 496 
 497 
Figure 2. Variations in hip shape identified by SSM. Mode 1 (a), Mode 3 (b) and Mode 4 (c) 498 
showed significant associations with KLG. Solid red line indicates +2sd, dotted blue line 499 
denotes -2sd.  500 
 501 
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